Inclusion Criteria:

          -  Patients with advanced malignancies, either refractory to standard therapy or for
             which no effective standard therapy is available, unless the drugs in the protocol are
             part of the standard of care for a specific diagnosis

               -  Predominant hepatic metastasis is defined as at least 50% of the total tumor
                  burden involving the liver

               -  An aberrant PI3K pathway such as PIK3CA mutations or PTEN loss, is detected in a
                  CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory

               -  For patients who are enrolled into the arm of FOLFOX6 plus bevacizumab, they must
                  have metastatic colorectal cancer with predominant hepatic metastases

               -  For patients who are enrolled into the arm of DAT, they must have predominant
                  hepatic metastases harboring an aberrant PI3K pathway

          -  Patients must have measurable or evaluable disease, as defined by Response Evaluation
             Criteria in Solid Tumors (RECIST) 1.1

          -  Women of child-bearing potential (women who are not postmenopausal for at least one
             year or are not surgically sterile) and men must agree to use adequate contraception
             (e.g., hormonal, barrier device, or abstinence) prior to study entry, for the duration
             of study participation, and for 30 days after the last dose of the study agents

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 to 2

          -  Neutrophils >= 1,500/uL

          -  Platelets >= 100,000/uL

          -  Total bilirubin =< 1.5 x ULN (upper limit of normal) (except patients with Gilbert's
             syndrome, who must have a total bilirubin =< 3.0 mg/dL)

          -  Alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN if liver metastases persist

          -  Serum creatinine =< 1.5 mg/dL or calculated creatinine clearance >= 50 mL/minutes

          -  Patients should be able to read and fully understand the requirements of the trial, be
             willing to comply with all trial visits and assessments, and be willing and able to
             sign an Institutional Reviewed Board (IRB)-approved written informed consent document

          -  Patients may receive palliative radiation therapy immediately before or during the
             treatment if the radiation therapy is not delivered to the sole target lesions

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring intravenous antibiotics, symptomatic congestive heart failure (New
             York Heart Association [NYHA] class III or IV), unstable angina pectoris, uncontrolled
             systemic hypertension (systolic blood pressure [BP] > 140 mm Hg, diastolic BP > 90 mm
             Hg), left ventricular ejection fraction < 50%, active bleeding, or psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Patients who have not recovered from major surgical procedure, or significant
             traumatic injury (i.e., patients still need additional medical care for these issues)

          -  History of allergic reactions to the study drugs or their analogs, or any component of
             the products, or sensitive to conductive hydrogels used on electrocardiogram (ECG)
             stickers or transcutaneous electrical nerve stimulation (TENS) electrodes

          -  Any treatment specific for tumor control within 3 weeks of drugs; or within 2 weeks if
             cytotoxic agents were given weekly (within 6 weeks for nitrosoureas or mitomycin C),
             or within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects
             lasting fewer than 4 days (that includes, but is not limited to, erlotinib, sorafenib,
             sunitinib, bortezomib, and similar agents), or failure to recover from the toxic
             effect of any of these therapies prior to study entry

          -  Symptomatic primary tumors or metastasis of brain and/or central nervous system that
             are uncontrolled with antiepileptics and requiring high doses of steroids

          -  Implanted pacemaker, defibrillator, nerve stimulator or other active electronic
             medical devices

          -  Corrected QT interval (QTc) is greater than 480 milliseconds (msec) at screening, or
             documented clinically significant arrhythmias. The QTc formula Bazett will be used for
             assessing subject eligibility

          -  History of stroke or transient ischemic attack, peripheral vascular disease, active
             gastric or duodenal ulcer, abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess within 6 months prior to study enrollment

          -  Patients with known human immunodeficiency virus infection, active hepatitis B or C

          -  Women who are pregnant will be excluded from the study